{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T04:25:50Z","timestamp":1743049550989,"version":"3.40.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024003","name":"Damanhour University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The well-known anti-seizure medication, sodium valproate, is used to treat epilepsy, bipolar disorder, and other mental health conditions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aimed to determine how pharmacist counseling intervention affected the prescribing patterns and usage of sodium valproate in patients with neurological diseases. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patient prescriptions were analyzed in a quasi-experimental pretest\u2013posttest design research, at baseline and after three months of pharmacy educational intervention. Medical history, drug-drug interactions, antipsychotic combinations, medication errors, and dosages were among the information gathered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The reviewed prescriptions observed trend towards antipsychotic combination, 15 (2.5%) prescriptions had five medications, while 18 (3%) contained four, 169 (28.2%) containing three, 329 (54.8%) containing two, and 69 (11.5%) containing one, antipsychotic. Of the reviewed prescriptions, 6% had possible drug-drug interactions. However, following a 3-month pharmacy educational intervention, the tendency toward antipsychotic combination decreased significantly to 262 (52%) with prescriptions for 2 antipsychotics and 163 (32.3%) with 3 antipsychotics. Likewise, the decreases in medication errors related to frequency and dosage were 8 (1.6%) <jats:italic>vs.<\/jats:italic> 29 (4.8%) and 6 (1.2%) <jats:italic>vs.<\/jats:italic> 35 (5.8%), compared to baseline respectively. Additionally, medication adherence was raised significantly (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.000) from 50 (8.3%) to 338 (67.1%) after the intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>More precise regulations\u00a0should be placed on sodium valproate prescription patterns and usage, throughout implemented pharmacist initiative in patients counselling, provision of health education and therapeutic monitoring to improve health-related quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>This study was registered on clinicaltrial.gov with an identification code NCT05830981. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05830981\" ext-link-type=\"uri\">https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05830981<\/jats:ext-link> (First Posted: April 26, 2023).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s12913-025-12483-5","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T02:34:37Z","timestamp":1743042877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of prescribing patterns of sodium valproate in neurological disease patients: a quasi-experimental pretest\u2013posttest design study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-3993","authenticated-orcid":false,"given":"Rehab H.","family":"Werida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salima","family":"El-Sherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"Shoshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4539-8940","authenticated-orcid":false,"given":"Naglaa F.","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"Pt A","key":"12483_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.yebeh.2019.06.003","volume":"98","author":"M Ma","year":"2019","unstructured":"Ma M, Peng Q, Gu X, Hu Y, Sun S, Sheng Y, Wang P, Ma H, Zhou B. Pharmacist impact on adherence of valproic acid therapy in pediatric patients with epilepsy using active education techniques. Epilepsy Behav. 2019;98(Pt A):14\u20138. https:\/\/doi.org\/10.1016\/j.yebeh.2019.06.003.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"12483_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/(sici)1520-6394(1997)6:1<10::aid-da2>3.0.co;2-9","volume":"6","author":"DC Steffens","year":"1997","unstructured":"Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety. 1997;6(1):10\u20138. https:\/\/doi.org\/10.1002\/(sici)1520-6394(1997)6:1%3c10::aid-da2%3e3.0.co;2-9. PMID: 9394870.","journal-title":"Depress Anxiety"},{"issue":"5","key":"12483_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1007\/s11096-023-01643-4","volume":"45","author":"M Stuhec","year":"2023","unstructured":"Stuhec M, Hahn M, Taskova I, et al. Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health. Int J Clin Pharm. 2023;45(5):1286\u201392. https:\/\/doi.org\/10.1007\/s11096-023-01643-4.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"12483_CR4","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1007\/s11096-021-01306-2","volume":"43","author":"M Stuhec","year":"2021","unstructured":"Stuhec M. Clinical pharmacist consultant in primary care settings in Slovenia focused on elderly patients on polypharmacy: successful national program from development to reimbursement. Int J Clin Pharm. 2021;43(6):1722\u20137. https:\/\/doi.org\/10.1007\/s11096-021-01306-2.","journal-title":"Int J Clin Pharm"},{"issue":"Pt A","key":"12483_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.yebeh.2019.06.003","volume":"98","author":"M Ma","year":"2019","unstructured":"Ma M, Peng Q, Gu X, et al. Pharmacist impact on adherence of valproic acid therapy in pediatric patients with epilepsy using active education techniques. Epilepsy Behav. 2019;98(Pt A):14\u20138. https:\/\/doi.org\/10.1016\/j.yebeh.2019.06.003.","journal-title":"Epilepsy Behav."},{"key":"12483_CR6","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","volume":"71","author":"E Faught","year":"2008","unstructured":"Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality findings from the RANSOM Study. Neurology. 2008;71:1572\u20138.","journal-title":"Neurology"},{"key":"12483_CR7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1528-1167.2008.01794.x","volume":"50","author":"RE Faught","year":"2009","unstructured":"Faught RE, Weiner JR, Guerin A, Cunnington MC, Duh MS. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia. 2009;50:501\u20139.","journal-title":"Epilepsia"},{"key":"12483_CR8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1528-1167.2007.01414.x","volume":"49","author":"KL Davis","year":"2008","unstructured":"Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008;49:446\u201354.","journal-title":"Epilepsia"},{"issue":"5","key":"12483_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1440-1614.2002.01037.x","volume":"36","author":"D Castle","year":"2002","unstructured":"Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients\u2019 perspective. Aust N Z J Psychiatry. 2002;36(5):633\u201341. https:\/\/doi.org\/10.1046\/j.1440-1614.2002.01037.x.","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"12483_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1440-0979.2004.00340.x","volume":"13","author":"B Happell","year":"2004","unstructured":"Happell B, Manias E, Roper C. Wanting to be heard mental health consumers\u2019 experiences of information about medication. Int J Ment Health Nurs. 2004;13(4):242\u20138. https:\/\/doi.org\/10.1111\/j.1440-0979.2004.00340.x.","journal-title":"Int J Ment Health Nurs"},{"issue":"12","key":"12483_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/gps.1407","volume":"20","author":"J Snowdon","year":"2005","unstructured":"Snowdon J, Day S, Baker W. Why and how antipsychotic drugs are used in 40 Sydney nursing homes. Int J Geriatr Psychiatry. 2005;20(12):1146\u201352. https:\/\/doi.org\/10.1002\/gps.1407.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"12483_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/intqhc\/12.6.475","volume":"12","author":"RR Owen","year":"2000","unstructured":"Owen RR, Thrush CR, Kirchner JE, et al. Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose. Int J Qual Health Care. 2000;12(6):475\u2013782. https:\/\/doi.org\/10.1093\/intqhc\/12.6.475.","journal-title":"Int J Qual Health Care"},{"issue":"1","key":"12483_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/qshc.2003.006338","volume":"13","author":"C Paton","year":"2004","unstructured":"Paton C, Lelliott P. The use of prescribing indicators to measure the quality of care in psychiatric inpatients. QualSaf Health Care. 2004;13(1):40\u20135. https:\/\/doi.org\/10.1136\/qshc.2003.006338.","journal-title":"QualSaf Health Care"},{"issue":"7","key":"12483_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1192\/pb.27.7.266","volume":"27","author":"D Meagher","year":"2003","unstructured":"Meagher D, Moran M. Sub-optimal prescribing in an adult community mental health service: prevalence and determinants. Psychiatr Bull. 2003;27(7):266\u201370. https:\/\/doi.org\/10.1192\/pb.27.7.266.","journal-title":"Psychiatr Bull"},{"key":"12483_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1046\/j.1440-1665.2000.00264.x","volume":"8","author":"T Callaly","year":"2000","unstructured":"Callaly T, Trauer T. Patterns of use of antipsychotic medication in a regional community mental health service. Australas Psychiatry. 2000;8:220\u20134. https:\/\/doi.org\/10.1046\/j.1440-1665.2000.00264.x.","journal-title":"Australas Psychiatry"},{"issue":"3","key":"12483_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1023\/b:phar.0000026800.13888.b0","volume":"26","author":"R Viola","year":"2004","unstructured":"Viola R, Csukonyi K, Doro P, et al. Reasons for polypharmacy among psychiatric patients. Pharm World Sci. 2004;26(3):143\u20137. https:\/\/doi.org\/10.1023\/b:phar.0000026800.13888.b0.","journal-title":"Pharm World Sci"},{"issue":"7\u20138","key":"12483_CR17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1345\/aph.1C073","volume":"37","author":"KN van Dijk","year":"2003","unstructured":"van Dijk KN, Pont LG, de Vries CS, et al. Prescribing indicators for evaluating drug use in nursing homes. Ann Pharmacother. 2003;37(7\u20138):1136\u201341. https:\/\/doi.org\/10.1345\/aph.1C073.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"12483_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/ageing\/32.1.102","volume":"32","author":"CA Oborne","year":"2003","unstructured":"Oborne CA, Hooper R, Swift CG, et al. Explicit, evidence-based criteria to assess the quality of prescribing to elderly nursing home residents. Age Ageing. 2003;32(1):102\u20138. https:\/\/doi.org\/10.1093\/ageing\/32.1.102.","journal-title":"Age Ageing"},{"issue":"1","key":"12483_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jppr200131119","volume":"31","author":"RA Elliott","year":"2001","unstructured":"Elliott RA, Woodward MC, Oborne CA. Indicators of prescribing quality for elderly hospital inpatients. Aust J Hosp Pharm. 2001;31(1):19\u201325. https:\/\/doi.org\/10.1002\/jppr200131119.","journal-title":"Aust J Hosp Pharm"},{"issue":"25","key":"12483_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2165\/00044011-200323050-00001","volume":"23","author":"P Gareri","year":"2003","unstructured":"Gareri P, De Fazio P, Stilo M, et al. Conventional and atypical antipsychotics in the elderly: a review. Clin Drug Investig. 2003;23(25):287\u2013322. https:\/\/doi.org\/10.2165\/00044011-200323050-00001.","journal-title":"Clin Drug Investig"},{"issue":"10","key":"12483_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695\u2013714. https:\/\/doi.org\/10.2165\/00023210-200216100-00004. PMID: 12269862.","journal-title":"CNS Drugs"},{"issue":"2","key":"12483_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/01.wnf.0000154221.37887.73","volume":"28","author":"J Fleming","year":"2005","unstructured":"Fleming J, Chetty M. Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005;28(2):96\u2013101. https:\/\/doi.org\/10.1097\/01.wnf.0000154221.37887.73.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"12483_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/1060028020947173)","volume":"55","author":"NJ Quinn","year":"2021","unstructured":"Quinn NJ, Hohlfelder B, Wanek MR, Duggal A, Torbic H. Prescribing Practices of Valproic Acid for Agitation and Delirium in the Intensive Care Unit. Ann Pharmacother. 2021;55(3):311\u20137. https:\/\/doi.org\/10.1177\/1060028020947173).","journal-title":"Ann Pharmacother"},{"key":"12483_CR24","unstructured":"World Health Organization. How to investigate drug use in health facilities. Geneva: World Health Organization, 1993. http:\/\/apps.who.int\/medicinedocs\/pdf\/s2289e\/s2289e.pdf."},{"key":"12483_CR25","unstructured":"Rahman M, Nguyen H. Valproic Acid. In: StatPearls. Treasure Island: StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559112\/. Updated 2022 Jul 4."},{"key":"12483_CR26","unstructured":"Panayiotopoulos CP. The Epilepsies: Seizures, Syndromes and Management. Oxford shire: Bladon Medical Publishing; 2005. Chapter 14, Pharmacopoeia of Prophylactic Antiepileptic Drugs.\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK2597\/"},{"issue":"1","key":"12483_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/2141-9248.109499","volume":"3","author":"A1 Adesola","year":"2013","unstructured":"Adesola A1, Anozie I, Erohubie P, James B. Prevalence, and correlates of \u201chigh dose\u201d antipsychotic prescribing: findings from a hospital audit. Ann Med Health Sci Res. 2013;3(1):62\u20136. https:\/\/doi.org\/10.4103\/2141-9248.109499.","journal-title":"Ann Med Health Sci Res."},{"key":"12483_CR28","doi-asserted-by":"crossref","unstructured":"Schachter SC. Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects. Post TW, ed. UpToDate. Waltham: UpToDate Inc. http:\/\/www.uptodate.com. Accessed 21\u00a0Nov 2018.","DOI":"10.1097\/01.COT.0000532445.33831.21"},{"key":"12483_CR29","doi-asserted-by":"crossref","unstructured":"Schachter SC. Overview of the management of epilepsy in adults. Post TW, ed. UpToDate. Waltham: UpToDate Inc. http:\/\/www.uptodate.com. Accessed 11\u00a0Jul 2019.","DOI":"10.1097\/01.COT.0000554500.76160.69"},{"issue":"Pt A","key":"12483_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.yebeh.2019.06.003","volume":"98","author":"M Ma","year":"2019","unstructured":"Ma M, Peng Q, Gu X, Hu Y, Sun S, Sheng Y, Wang P, Ma H, Zhou B. Epilepsy Pharmacist impact on adherence of valproic acid therapy in pediatric patients with epilepsy using active education techniques. Behav. 2019;98(Pt A):14\u20138. https:\/\/doi.org\/10.1016\/j.yebeh.2019.06.003.","journal-title":"Behav."},{"key":"12483_CR31","unstructured":"National Collaborating Centre for Mental Health (UK). Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester: British Psychological Society; 2010. National Institute for Health and Clinical Excellence: Guidance. PMID: 2213243"},{"key":"12483_CR32","doi-asserted-by":"publisher","unstructured":"Aremu TO, Oluwole OE, Adeyinka KO, Schommer JC. Medication Adherence and Compliance: Recipe for Improving Patient Outcomes. Pharmacy (Basel). 2022;10(5):106. https:\/\/doi.org\/10.3390\/pharmacy10050106. PMID:36136839;PMCID:PMC9498383.","DOI":"10.3390\/pharmacy10050106"},{"key":"12483_CR33","doi-asserted-by":"crossref","unstructured":"Landau S. 2004. A handbook of statistical analyses using SPSS, CRC","DOI":"10.1201\/9780203009765"},{"issue":"5","key":"12483_CR34","first-page":"1069","volume":"5","author":"K Lahon","year":"2011","unstructured":"Lahon K, Shetty H, Paramel A, Sharma G. A retrospective drug utilization study of antidepressants in the psychiatric unit of a tertiary care hospital. J Clin Diagn Res. 2011;5(5):1069\u201375 https:\/\/www.jcdr.net\/articles\/pdf\/1521\/39-%202864.","journal-title":"J Clin Diagn Res"},{"issue":"4","key":"12483_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4236\/pp.2012.34055","volume":"3","author":"K Al Khaja","year":"2012","unstructured":"Al Khaja K. Antipsychotic and anticholinergic drug prescribing pattern in psychiatry: extent of evidence-based practice in Bahrain. Pharmacol Pharm. 2012;3(4):409\u201316. https:\/\/doi.org\/10.4236\/pp.2012.34055.","journal-title":"Pharmacol Pharm"},{"issue":"2","key":"12483_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/cia.s2468","volume":"3","author":"RL Bushardt","year":"2008","unstructured":"Bushardt RL, Massey EB, Simpson TW, et al. Polypharmacy: misleading, but manageable. ClinInterv Aging. 2008;3(2):383\u20139. https:\/\/doi.org\/10.2147\/cia.s2468.","journal-title":"ClinInterv Aging"},{"issue":"6","key":"12483_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.18553\/jmcp.2010.16.6.393","volume":"16","author":"JL G\u00f6ren","year":"2010","unstructured":"G\u00f6ren JL, Beck SE, Mills BJ, Shtasel DL, Dufresne RL. Development and delivery of a quality improvement program to reduce antipsychotic polytherapy. J Manag Care Pharm. 2010;16(6):393\u2013401. https:\/\/doi.org\/10.18553\/jmcp.2010.16.6.393.","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"12483_CR38","first-page":"S3","volume":"35","author":"D Chadwick","year":"1994","unstructured":"Chadwick D. Standard approach to antiepileptic drug treatment in the United Kingdom. Epilepsia. 1994;35(4):S3-10.","journal-title":"Epilepsia"},{"issue":"7","key":"12483_CR39","first-page":"392","volume":"35","author":"MM Goldenberg","year":"2010","unstructured":"Goldenberg MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P T. 2010;35(7):392\u2013415 PMID: 20689626; PMCID: PMC2912003.","journal-title":"P T."},{"issue":"12","key":"12483_CR40","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.7860\/JCDR\/2013\/6760.3885","volume":"7","author":"KB Thakkar","year":"2013","unstructured":"Thakkar KB, Jain MM, Billa G, Joshi A, et al. A drug utilization study of psychotropic drugs prescribed in the psychiatry outpatient department of a tertiary care hospital. J Clin Dagn Res. 2013;7(12):2759\u201364. https:\/\/doi.org\/10.7860\/JCDR\/2013\/6760.3885.","journal-title":"J Clin Dagn Res"},{"key":"12483_CR41","doi-asserted-by":"crossref","DOI":"10.1201\/b14455","volume-title":"The Maudsley 2005\u20132006 prescribing guidelines","author":"D Taylor","year":"2005","unstructured":"Taylor D, Paton C, Kerwin R. The Maudsley 2005\u20132006 prescribing guidelines. London: Taylor and Francis; 2005."},{"issue":"3","key":"12483_CR42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2165\/00003088-199631030-00004","volume":"31","author":"E Spina","year":"1996","unstructured":"Spina E, Pisani F, Perucca F. Clinically significant drug interactions with carbamazepine. Clin Pharmacokinet. 1996;31(3):198\u2013214. https:\/\/doi.org\/10.2165\/00003088-199631030-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"12483_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2165\/00044011-200626070-00003","volume":"26","author":"JS Bell","year":"2006","unstructured":"Bell JS, Whitehead P, Aslani P, et al. Drug related problems in the community setting: pharmacists\u2019 findings and recommendations for people with mental illnesses. Clin Drug Investig. 2006;26(6):415\u201325. https:\/\/doi.org\/10.2165\/00044011-200626070-00003.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"12483_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/01.jcp.0000150217.51433.9f","volume":"25","author":"DB Merrill","year":"2005","unstructured":"Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psycho pharmacol. 2005;25(1):32\u201341. https:\/\/doi.org\/10.1097\/01.jcp.0000150217.51433.9f.","journal-title":"J Clin Psycho pharmacol"},{"issue":"5","key":"12483_CR45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396. https:\/\/doi.org\/10.2165\/00002018-200629050-00003.","journal-title":"Drug Saf"},{"issue":"1","key":"12483_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13643-020-1274-3.PMID:31948489;PMCID:PMC6966860","volume":"9","author":"A Semahegn","year":"2020","unstructured":"Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9(1):17. https:\/\/doi.org\/10.1186\/s13643-020-1274-3.PMID:31948489;PMCID:PMC6966860.","journal-title":"Syst Rev"},{"key":"12483_CR47","doi-asserted-by":"publisher","unstructured":"van Grootheest K1, van Puijenbroek EP, de Jong-van den Berg LT. Do pharmacists\u2019 report of adverse drug reactions reflect patients\u2019 concerns? Pharm World Sci 2004; 26(3): 155\u2013159. https:\/\/doi.org\/10.1023\/b:phar.0000026802.81401.bb","DOI":"10.1023\/b:phar.0000026802.81401.bb"},{"key":"12483_CR48","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2147\/PPA.S124028.PMID:28572723;PMCID:PMC5441662","volume":"11","author":"R AlAjmi","year":"2017","unstructured":"AlAjmi R, Al-Aqeel S, Baz S. The impact of a pharmacist-led educational interview on medication adherence of Saudi patients with epilepsy. Patient Prefer Adherence. 2017;11:959\u201364. https:\/\/doi.org\/10.2147\/PPA.S124028.PMID:28572723;PMCID:PMC5441662.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"12483_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/nedt.2007.3.1.117.PMID:19300542;PMCID:PMC2654533","volume":"3","author":"J Eatock","year":"2007","unstructured":"Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat. 2007;3(1):117\u201331. https:\/\/doi.org\/10.2147\/nedt.2007.3.1.117.PMID:19300542;PMCID:PMC2654533.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"12483_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5001\/omj.2011.38.PMID:22043406;PMCID:PMC3191684","volume":"26","author":"B Jimmy","year":"2011","unstructured":"Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26(3):155\u20139. https:\/\/doi.org\/10.5001\/omj.2011.38.PMID:22043406;PMCID:PMC3191684.","journal-title":"Oman Med J"},{"issue":"1","key":"12483_CR51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40814-022-01071-7.PMID:35655244;PMCID:PMC9161485","volume":"8","author":"Y Nanaumi","year":"2022","unstructured":"Nanaumi Y, Yoshitani A, Onda M. Impact of interventions by a community pharmacist on care burden for people with dementia: development and randomized feasibility trial of an intervention protocol. Pilot Feasibility Stud. 2022;8(1):118. https:\/\/doi.org\/10.1186\/s40814-022-01071-7.PMID:35655244;PMCID:PMC9161485.","journal-title":"Pilot Feasibility Stud"},{"issue":"5","key":"12483_CR52","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s11096-013-9817-5","volume":"35","author":"C Chen","year":"2013","unstructured":"Chen C, Lee DS, Hie SL. The impact of pharmacist\u2019s counseling on pediatric patients\u2019 caregiver\u2019s knowledge on epilepsy and its treatment in a tertiary hospital. Int J Clin Pharm. 2013;35(5):829\u201334. https:\/\/doi.org\/10.1007\/s11096-013-9817-5. Epub 2013 Jul 9 PMID: 23836322.","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"12483_CR53","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2147\/PPA.S93046.PMID:27110102;PMCID:PMC4831598","volume":"4","author":"SM McLean","year":"2016","unstructured":"McLean SM, Booth A, Gee M, Salway S, Cobb M, Bhanbhro S, Nancarrow SA. Appointment reminder systems are effective but not optimal: results of a systematic review and evidence synthesis employing realist principles. Patient Prefer Adherence. 2016;4(10):479\u201399. https:\/\/doi.org\/10.2147\/PPA.S93046.PMID:27110102;PMCID:PMC4831598.","journal-title":"Patient Prefer Adherence"},{"key":"12483_CR54","doi-asserted-by":"publisher","unstructured":"Borges M, Vilela Rodrigues JP, Freato Gon\u00e7alves AM, Silveira Almeida Campos M, Rossi Varallo F, Barbosa Zanetti MO, Regis Leira Pereira L. An Analysis of Drug-Related Problems in the Neurology Ward of a Tertiary Teaching Hospital: A Cross-Sectional Study. Cureus. 2024;16(7):e63829. https:\/\/doi.org\/10.7759\/cureus.63829. PMID: 39099928; PMCID: PMC11297551.","DOI":"10.7759\/cureus.63829"},{"key":"12483_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2023.100302.PMID:37538991;PMCID:PMC10393785","volume":"11","author":"N Jimmy","year":"2023","unstructured":"Jimmy N, Upadhya M, Jaison JM, Sidheque S, Sundaramurthy H, Nemichandra SC, Paneyala S, Ramesh M, Sri Harsha C, Syed J, Pal N. A Clinical Pharmacist-led Approach on Reducing Drug Related Problems Among Patients with Neurological Disorders: An Interventional Study. Explor Res Clin Soc Pharm. 2023;11: 100302. https:\/\/doi.org\/10.1016\/j.rcsop.2023.100302.PMID:37538991;PMCID:PMC10393785.","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"6","key":"12483_CR56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.9740\/mhc.2020.11.358","volume":"10","author":"A Werremeyer","year":"2020","unstructured":"Werremeyer A, Bostwick J, Cobb C, et al. Impact of pharmacists on outcomes for patients with psychiatric or neurologic disorders. Ment Health Clin. 2020;10(6):358\u201380. https:\/\/doi.org\/10.9740\/mhc.2020.11.358. Published 2020 Nov 5.","journal-title":"Ment Health Clin."},{"issue":"9","key":"12483_CR57","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11920-017-0809-3","volume":"19","author":"D Gotlib","year":"2017","unstructured":"Gotlib D, Ramaswamy R, Kurlander JE, DeRiggi A, Riba M. Valproic Acid in Women and Girls of Childbearing Age. Curr Psychiatry Rep. 2017;19(9):58. https:\/\/doi.org\/10.1007\/s11920-017-0809-3.","journal-title":"Curr Psychiatry Rep"},{"key":"12483_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2017.01.002","volume":"46","author":"R Shawahna","year":"2017","unstructured":"Shawahna R, Atrash A, Jebril A, Khalaf A, Shaheen E, Tahboosh H. Evaluation of pharmacists\u2019 knowledge of women\u2019s issues in epilepsy: A cross-sectional study in Palestinian pharmacy practice. Seizure. 2017;46:1\u20136. https:\/\/doi.org\/10.1016\/j.seizure.2017.01.002.","journal-title":"Seizure"},{"issue":"22","key":"12483_CR59","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.1989.03420220087032","volume":"261","author":"JA Cramer","year":"1989","unstructured":"Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique [published correction appears in JAMA 1989 Sep 15;262(11):1472]. JAMA. 1989;261(22):3273\u20137.","journal-title":"JAMA"},{"issue":"8","key":"12483_CR60","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/s0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296\u2013310. https:\/\/doi.org\/10.1016\/s0149-2918(01)80109-0.","journal-title":"Clin Ther"},{"issue":"4","key":"12483_CR61","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/s1525-5050(02)00037-9","volume":"3","author":"JA Cramer","year":"2002","unstructured":"Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3(4):338\u201342. https:\/\/doi.org\/10.1016\/s1525-5050(02)00037-9.","journal-title":"Epilepsy Behav"},{"key":"12483_CR62","doi-asserted-by":"crossref","unstructured":"Ernst LL, Harden CL, Pennell PB, et al. Medication adherence in women with epilepsy who are planning pregnancy. Epilepsia. 2016;57(12):2039\u201344. https:\/\/doi.org\/10.1111\/epi.13586 .","DOI":"10.1111\/epi.13586"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12483-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12483-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12483-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T02:34:57Z","timestamp":1743042897000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12483-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12483"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12483-5","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Helsinki Declaration's guidelines were followed in conducting this study. The Research Ethics Committee of Faculty of Pharmacy-Tanta University approved the protocol of the study (Code number: TP\/RE\/2\/23p-006) on 2\/01\/2023. All subjects involved in the study gave their informed consent. This study was registered in the National ClinicalTrials.gov with Code No: NCT05830981 on 25th April, 2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"441"}}